logo
Plus   Neg
Share
Email

Toyota, Hino To Jointly Develop Heavy-Duty Fuel Cell Truck - Quick Facts

Japanese automakers Toyota Motor Corp. (TYT.L,TM) and Hino Motors, Ltd. announced Monday an agreement to jointly develop a heavy-duty fuel cell truck. The companies would also proceed with initiatives toward its practical use through verification tests and other means.

The heavy-duty fuel cell truck is based on Hino Profia, and is being developed using technologies of both Toyota and Hino. The chassis is specially designed with the optimum packaging for a fuel cell vehicle.

The powertrain is equipped with two Toyota fuel cell stacks that have been newly developed for Toyota's next Mirai and includes vehicle driving control that applies heavy-duty hybrid vehicle technologies, developed by Hino.

Both companies are developing electric vehicle technologies as part of their respective goals to reduce CO2 emissions by 2050. Fuel cell vehicles run on hydrogen.

The companies noted that heavy-duty trucks' environmental performance require major improvements for further reductions in CO2 emissions.

According to Hino internal research, heavy-duty trucks and buses with gross vehicle weight of over 3.5 tons account for about 60 percent of the total CO2 emissions from commercial vehicles in Japan, as of February 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>